Poland· PL-100088061

Atacand

A candesartan product containing candesartanum cilexetili, registered in Poland by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 16 of our 19 countries.

ATC C09CA06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAtacandATCC09CA06REGISTER NO.PL-100088061PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Candesartan is registered in 16 of 19 countries.

Countries holding a registration under ATC C09CA06 (candesartan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Candesartan · ATC C09CA06

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of candesartan costs, country by country.

Normalised to the WHO defined daily dose (8 mg), the median price runs from $0.15 in Italy to $0.36 in Switzerland — a ×2.3 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Candesartan · price per daily dose (8 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.36
  • ES Spain$0.21
  • IT Italy$0.15
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Candesartanum cilexetili
Manufacturer
CHEPLAPHARM Arzneimittel GmbH
Country
Poland (PL)
ATC code
C09CA06
ATC class
Candesartan
Defined daily dose
8 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909990430017
  • gtin
    05909990430024
  • gtin
    05909990430031
  • gtin
    05909991213596

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for candesartan.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Candesartan · interactions on record

81 records

81 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f2fddc0c-58ec-4262-8808-ff885936b451
GET /v1/drugs/f2fddc0c-58ec-4262-8808-ff885936b451?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "8 mg",
  "packaging": "05909990430017 ¦ Rp ¦ 13485\n1 blister 14 tabl.\n05909990430024 ¦ Rp ¦ 13486\n1 blister 28 tabl.\n05909990430031 ¦ Rp ¦ 13487\n1 butelka 100 tabl.\n05909991213596 ¦ Rp ¦ 107432\n1 blister 90 tabl.",
  "substance": "Candesartanum cilexetili 8 mg",
  "common_name": "Candesartanum cilexetili",
  "pl_product_id": "100088061",
  "pozwolenie_nr": "04300",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}

See everything about candesartan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.